Medtronic is taking another shot at renal denervation to treat drug-resistant hypertension, a year after a pivotal trial for its key product in the space failed to meet its efficacy endpoint.
A massive Intuitive Surgical-backed study finds that using its da Vinci surgical robot to treat kidney cancer is improves outcomes and save costs over the long term.
Cardiac device-maker Medtronic and dialysis-provider DaVita Healthcare Partners plan to team up to identify and study cardiac arrhythmia in patients undergoing dialysis.
Home hemodialysis device maker NxStage Medical touts a new study showing that kidney patients who underwent frequent home hemodialysis had a better quality of life and lower risk of death than those who underwent peritoneal dialysis.
Astute Medical is in line to receive up to $30 million from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test.
Astute Medical said it's in line to receive up to $30 million under a standing loan agreement from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test, and could receive an additional $10 million if it hits certain revenue milestones.
Another trial of Medtronic's Symplicity renal denervation device in treating hypertension shows no benefit compared with a sham procedure.
New data from CardioMEMs CHAMPION clinical trial shows that the company's implanted pulmonary artery pressure monitor helps reduce heart failure hospitalizations without compromising kidney function in patients with renal failure.
St. Jude Medical (NYSE:STJ) subsidiary CardioMEMs touted new study results this week showing that its implanted heart monitor is safe and effective in patients with chronic kidney disease.